ESR1 and breast cancer: Since PKD1 overexpression confers resistance to antioestrogen ICI 182,780 in MCF-7 ERα-positive breast cancer cells (Fig. 4), we investigated the possible relationship between PKD1 expression level and patient responsiveness to the most common antiestrogen agent in clinical use, i.e. tamoxifen.